πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 92 of 173

  1. US 9200054

    Somatostatin analogs with inhibitory activity to growth hormone release

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9200024

    Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9200015

    Inositol hexakisphosphate analogs and uses thereof

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9198989

    Radioactive bone cement

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9198959

    Adenovirus vaccine vector and methods of use

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9198915

    Methods involving aldose reductase inhibitors

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9198882

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9198950

    Recombinant bacterium comprising a toxin/antitoxin system

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9200265

    Anti-cocaine compositions and treatment

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9192590

    Enterically coated cysteamine, cystamine and derivatives thereof

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9193956

    Adeno-associated virus virions with variant capsid and methods of use thereof

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9192650

    Methods of inhibiting photoreceptor apoptosis by eliciting the Faim2 antiapoptotic pathway

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9192578

    Hot-melt extrusion of modified release multi-particulates

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9192630

    Transplantation of neural cells

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9192629

    Isolated renal cells and uses thereof

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9192644

    Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9192628

    Treatment method for relapsing-remitting multiple sclerosis

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9186400

    Compositions for stimulation of mammalian innate immune resistance to pathogens

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9187529

    Cationic peptides and use of such peptides for inhibiting exotoxin production

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9187523

    Substrate peptide sequences for plague plasminogen activator and uses thereof

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9186417

    Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9186340

    Ischemia/reperfusion protection compositions and methods of using

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9186362

    Methods involving aldose reductase inhibitors

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9187413

    Peripherally restricted FAAH inhibitors

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9187541

    Anti-microbial peptides and methods of use thereof

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9180102

    Methods for fabricating nano and microparticles for drug delivery

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9182412

    Borrelia diagnostics and screening methods

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9180196

    Photodegradable groups for tunable polymeric materials

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9180395

    Porous thin films

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9180212

    Ξ²-amyloid plaque imaging agents

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9180144

    Decellularisation of tissue matrices for bladder implantation

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9180143

    Decellularisation of tissue matrices for bladder implantation

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9181330

    Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9173975

    Reparative cell delivery via hyaluronic acid vehicles

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9175349

    Methods of diagnosing endometriosis

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9174917

    Bexarotene analogs

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9173862

    Methods and compositions for treating and identifying compounds to treat age-related macular degeneration

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9173839

    Anionic lipids and lipid nano-structures and methods of producing and using same

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9175058

    Soluble immune response suppressor polypeptides and treatment of multiple sclerosis and other autoimmune diseases

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9173943

    Imprinted polymer nanoparticles

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9173966

    Luciferin derivatives from bicyclic reactants and aminothiol derivatives and methods of use thereof

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9174990

    2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purines as antiviral agents

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9175041

    Crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline, and methods for preparing dolamethylleuine and dolaphenvaline

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9175906

    Drug particles from freezing onto a surface

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9168261

    Compositions and methods for cartilage repair

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9168262

    Estriol therapy for multiple sclerosis and other autoimmune diseases

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9169321

    Activatable binding polypeptides and methods of identification and use thereof

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9169509

    Topoisomerase 2b as a predictor of susceptibility to anthracycline-induced cardiotoxicity

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.